1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

How China Inc. Aims To Take Over Cell Therapy Dominance

Speed, Partnerships Shine for Small CAR-T Players

 
• By Brian Yang

Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.

Nanjing, China
NANJING-BASED IASO, SET UP IN 2017, AIMS TO FILE ITS CAR-T THERAPY NEXT YEAR IN CHINA • Source: Shutterstock

Despite no products having gained approval and the field being scattered with smaller players, China is poised to take a leading position in the fast-growing cancer treatment field of cell therapy. Among the many little-known players striving for the spotlight is IASO Bio, a Nanjing-based chimeric antigen T (CAR-T) cell therapy developer.

Founded in March 2017, IASO came into the spotlight after it garnered a respectable $60m in financing from Hillhouse Capital...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 
• By Andrew McConaghie

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Sarepta Voluntarily Stops Shipments Of Elevidys After Previously Refusing FDA Request

 
• By Mandy Jackson

The company had planned to keep its DMD gene therapy available for ambulatory patients, but now says pausing shipments may enable a better working relationship with the US FDA while safety labeling is updated.

More from Advanced Therapies

Sarepta Voluntarily Stops Shipments Of Elevidys After Previously Refusing FDA Request

 
• By Mandy Jackson

The company had planned to keep its DMD gene therapy available for ambulatory patients, but now says pausing shipments may enable a better working relationship with the US FDA while safety labeling is updated.

FDA Asked, Sarepta Refused To Stop Elevidys Shipments After Third Death With Gene Therapy Vector

 
• By Mandy Jackson

Sarepta knew about the death in a Phase I trial of SRP-9004 for LGMD when it recently revealed a restructuring plan, but did not disclose the event. The now-discontinued gene therapy candidate uses the same AAV vector as Elevidys, which has been linked to two DMD patient deaths.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.